CN1490016A - Bougie for treating virus hepatitis and preparing method thereof - Google Patents
Bougie for treating virus hepatitis and preparing method thereof Download PDFInfo
- Publication number
- CN1490016A CN1490016A CNA031253059A CN03125305A CN1490016A CN 1490016 A CN1490016 A CN 1490016A CN A031253059 A CNA031253059 A CN A031253059A CN 03125305 A CN03125305 A CN 03125305A CN 1490016 A CN1490016 A CN 1490016A
- Authority
- CN
- China
- Prior art keywords
- suppository
- fat
- viral hepatitis
- treatment
- acyclovir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound suppository for treating viral hepatitis by applying it through rectum contains monomethyl glycerrhetate, lentinan, acyclovir and liposoluble matrix. Its advantages are high curative effect, low toxic by-effect, no recurrence and low cost.
Description
Technical field
The present invention relates to the Chinese medicine and western medicine compound suppository, relate in particular to a kind ofly, be used for the treatment of suppository of viral hepatitis and preparation method thereof by rectally.
Background technology
Viral hepatitis is that a kind of infectious disease of common pilosity, particularly hepatitis B have 1.2 hundred million patients approximately in China.Though it is a lot of to treat the types of drugs of hepatitis B at present on the market, the sure medicine of curative effect has only a few kinds such as interferon, lamivudine.These medicines generally adopt the dosage form of injection or oral agents, and ubiquity the administration inconvenience, cost an arm and a leg, side effect is big, deficiency such as bounce-back is arranged after curing.There is the inconvenient problem of administration in injection; Oral administration is after gastrointestinal absorption, and medicine all will pass through liver detoxification, thereby has reduced the curative effect of medicine, has also increased the weight of the burden of liver of hepatitis, and medicine also has certain toxic and side effects to liver simultaneously, thereby liver is made the matter worse.
Summary of the invention
The objective of the invention is in order to solve the deficiency that the above-mentioned background technology exists, propose a kind of curative effect height, toxic and side effects little, be difficult for bounce-back, easy to use, the moderate suppository that is used for the treatment of viral hepatitis.
For achieving the above object, the present invention adopts following technical scheme: a kind of by rectally, the suppository that is used for the treatment of viral hepatitis, comprise Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide, acyclovir and fat-soluble substrate, wherein, every bolt contains Uralenic acid methyl ester 100-300mg, Lentinula edodes mycelium polysaccharide 30-50mg, acyclovir 50-150mg.
Also can comprise the absorption enhancer Capric acid sodium salt in this suppository, every bolt contains absorption enhancer Capric acid sodium salt 8-15mg.
Above-mentioned fat-soluble substrate can be semi-synthetic fatty acid glyceride, among cocoa butter, oleum sapii, tristearin, fractional distillation Petiolus Trachycarpi oil, fractionated coconut oil, Brazil wax, tripalmitin, glycerol tristearate, Tridocosanoin, Ke Kemu fat, hydrogenated vegetable oil, Tween-60, Tween-65 and the SUPPOCIRE any one, every bolt contains fat-soluble substrate 600-900mg.
The suppository that is used for the treatment of viral hepatitis of the present invention is the Chinese medicine and western medicine compound preparation, and wherein, Uralenic acid methyl ester, acyclovir all have antivirus action, and all can be used for the treatment of hepatitis B separately; Lentinula edodes mycelium polysaccharide is an immunostimulant, has the effect of strengthening the body resistance.The two is in conjunction with having the effect for the treatment of both the principal and secondary aspects of a disease.Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide are macromolecular compound, being difficult for seeing through mucous membrane of rectum behind the rectally is absorbed by body, and Capric acid sodium salt can be kept rectum epithelial cell gap structure, remove the Ca ion, leather structure on the lax rectum makes Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide be easy to see through the effect that mucous membrane of rectum enters performance kill virus in the body.
Another object of the present invention provides two kinds and prepares the above-mentioned preparation method that is used for the treatment of the suppository of viral hepatitis.
First kind of preparation method is: at first Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide, acyclovir were pulverized the 80-1O0 mesh sieve; Then it is joined in the fat-soluble substrate of 50-70 ℃ of thawing, grind to form the slurry of uniform and delicate while hot with colloid mill; Irritate mould, cooling forming, the demoulding, packing at last.
Second kind of preparation method is: at first Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide, acyclovir are joined in the fat-soluble substrate of 50-70 ℃ of thawing, grind to form the slurry of uniform and delicate while hot with colloid mill; Irritate mould, cooling forming, the demoulding, packing then.
The LD that the suppository that is used for the treatment of viral hepatitis of the present invention is carried out for the Chinese medicine and western medicine compound preparation
50Measure to confirm, when clinical application does not cause animal dead during greater than 60 times yet.Laboratory report is as follows:
One, summary
Suppository (hereinafter to be referred as the liver health bolt) maximum dose level that is used for the treatment of viral hepatitis of the present invention is 880mg/kg (is equivalent to clinical application 60 times), one day twice, and two (880mg) rectallies once, viewing duration is not seen rabbit death.
Two, purpose
Behind observer's rabbit rectum one twice-daily contact liver health bolt, because rectum absorbs toxic reaction and the death condition that is produced.
Three, be subjected to the reagent thing
1, medicine name: the suppository that is used for the treatment of viral hepatitis of the present invention: liver health bolt.
2, the unit of providing: Tongyao Medicine Co., Ltd., Wuhan City
3, be subjected to the test product lot number: 990301
4, excipient: semi-synthetic fatty acid glyceride, Capric acid sodium salt.
Four, reference substance
The blank bolt of excipient compares excipient dosage and amount of excipient in the liver health bolt consistent (not containing medicines such as acyclovir).
Five, animal
1, source: rabbit is provided by zoopery portion of Tongji Medical Univ.
2, body weight: 2kg.
3, sex: male and female half and half.
4, every treated animal number: N=4.
5, experiment condition: 25 ± 2 ℃ of temperature; Humidity 65%.
Six, dosage (mg/kg)
1, dosage setting: establish a heavy dose of group (surpassing clinical consumption more than 50 times) and the blank bolt matched group of corresponding excipient.
2, dosage: every rabbit is pressed weighing machine, 880mg/kg.
Seven, approach
Rectally, consistent with the clinical administration approach.
Eight, method
1, prerun: with two of rabbit, male and female each one, 440mg/kg (the clinical consumption of behaving 30 times) twice rectally on the one observed and do not seen any poisoning symptom and death condition in 7 days.According to the requirement of pre-test result and toxicology guide, estimate to intend the death that can not cause animal more than 60 times with clinical medicine dose, for this reason we with each two every days twice liver health bolt the rabbit rectally carried out acute toxicity formally test.
2, formal experiment: 8 of the heavy rabbit of 2kg, male and female half and half are divided into two groups at random, and one group is heavy dose of experiment administration group, and another group is the excipient matched group.Heavy dose of group is with a twice-daily (interval is 8 hours between twice), each two (880mg, quite 60 times of clinical dosage) liver health bolt send into the about 2cm of rectum place gently after with the warm water moistening, gently compressed the rabbit anus 15 minutes with have gentle hands then, treat to put into the box internal fixation respectively separately 4 hours after suppository melts, make 4 hours (front and back totally 8 hours) of rabbit rest subsequently; The same operation of administration for the second time.The excipient matched group is also undertaken by aforesaid operations.Observed 10 days variations such as the overall health of patients of observation rabbit, body weight, breathing, central nervous system, extremity activity, and record death time and quantity after the administration.
Nine, observation index
1, the observation period: 10 days.
2, toxic reaction: rabbit appetite is normal after the administration, and well-grown is not found the unusual of rabbit outward appearance and behavioral activity in the whole observation period, does not also see the signs of toxicity performance relevant with the drug intoxication reaction.
3, the postmortem of animal: put to death all animals on the 10th day, and dissected the cut-off intestinal, naked eyes are not seen obvious pathological changes.
Ten, result
Liver health bolt is to rabbit acute toxicity testing data
Group dosage (mg/kg) number of animals (only) death toll (only)
Liver health bolt group 880 40
Vehicle group-4 0
Conclusion: liver health bolt does not cause the death of animal for the acute toxicity test of rabbit twice rectally on the one with 880mg/kg (be equivalent to clinical application 60 times), the LD of prompting liver health bolt
50＞880mg/kg.
Under the very high situation of zoopery safety, the suppository that is used for the treatment of viral hepatitis of the present invention has been carried out clinic trial for the Chinese medicine and western medicine compound preparation.Clinical experiment is reported as follows:
The brief summary of liver health bolt treatment viral hepatitis clinical and experimental study
---provide by HuaZhong Science University, TongJi medical school, TongJi Hospital
One, physical data
(1), case is formed
Hospital of Tongji University shared liver health bolt is treated about acute and chronic hepatitis 500 examples over 2 years, remove and lose with anti-patient, obtain effective case 300 examples, wherein male 198 examples, woman's 102 examples, 30.2 ± 7.1 years old age, wherein acute hepatitis 112 examples, chronic hepatitis (being hepatitis B) 188 examples, all cases are my section's outpatient service and inpatient.
(2), usage and consumption
Acute hepatitis: liver health bolt 1 ball, the plug anus, sooner or later respectively once, the January course of treatment.
Chronic hepatitis: usage is the same, the 3-6 month course of treatment.
(3), grouping and observation index
1, acute hepatitis group: the acute hepatitis patient's (first, second, penta) who is GPT＞100U/L, the main liver health bolt of observing is to the mitigation of patient's symptom of digestive tract with fall Huang and fall enzyme effect and side effect, and is contrast with oral GANLIXIN JIAONANG 150mg tid+ liver glycosides 0.4g tid.
2, chronic hepatitis group: be the chronic viral hepatitis B patient, except that observing These parameters, mainly observe its effect of turning out cloudy to HBe Ag and HBVD DNA.
Two, result
(1), to the curative effect of acute hepatitis group, see Table I
Table I liver health bolt is to the curative effect of acute hepatitis
Symptom of digestive tract is delayed ALT recovery situation T-BIL
Separate rate ALT drop-out value natural rate of interest N decline average natural rate of interest
Liver health bolt
354± 40.8±
98.2(110/112) 96.4(108/112) 81 93.8(76/81)
Organize 89 10.1
Contrast 332 ± 42.0 ±
99.7(110/111) 94.6(106/112) 79 94.9(75/79)
Organize 91 11.1
Statistical results show, above-mentioned two groups of there was no significant differences that influence to above-mentioned three indexs.
(2) curative effect that chronic viral hepatitis B is turned out cloudy
188 routine chronic viral hepatitis B patients, HBs Ag are all positive, positive 59 examples of HBV wherein, and positive 12 examples of HBe Ag, HBe Ag and HBV DNA be positive 117 examples simultaneously.
The curative effect that Table II liver health bolt is turned out cloudy to chronic viral hepatitis B
The cloudy HBe of commentaries on classics of N HBV DNA Ag turns out cloudy, and HBV DNA+HBe Ag is cloudy to be changeed
HBV DNA positive person 59 30.5 (18/59)-----
HBe Ag positive person 12--33.3 (4/12)---
HBV DNA and
The equal positive person 117 29.9 (35/117) 28.2 (33/117) 27.4 (32/117) of HBe Ag
Its total effective rate 30.9% (58/188), 188 routine patients have 21 routine HBsAg cloudy commentaries on classics also to take place, negative conversion rate 11.0% when finish the course of treatment in addition.
(3) side effect, small number of patients with after the anus sense of discomfort is arranged, suppository drenched or continues medication with eliminating cold for resuscitation water all disappear, have 1 routine patient stomachache to occur and drug withdrawal does not count the curative effect statistics with the back.
Three, discuss
In the composition of liver health bolt, glycyrrhizin has good relieving hepatitis symptom, and hepatoprotective, fall enzyme, fall yellow effect, and have immunoregulation effect, its injection name potenlin, this medicine is still the main medicine for the treatment of hepatitis at present because of to the hepatitis determined curative effect.Lentinan is an immunostimulant, and acycloguanosine is an antiviral agents, both to viral hepatitis particularly the curative effect of hepatitis B all by being affirmed both at home and abroad.But both oral absorption are relatively poor, and particularly acycloguanosine oral absorption rate 30-40% only needs 6 administrations every day, and are extremely inconvenient, limited its application.They are made suppository, add solubilizing agent and short absorbent simultaneously, overcome above-mentioned shortcoming well, each medicine is worked in coordination with play a role.
Promote that cloudy commentaries on classics of hepatitis B virus is the difficult point for the treatment of hepatitis B at present.Interferon is that the authority who recommends at present both at home and abroad treats measure, and the negative conversion rate of its HBV DNA and/or HBe Ag is about about 40%, but the expense costliness, side effect is many and more serious, so can only use in small number of patients.Though the antiviral curative effect of liver health bolt is a little less than interferon, expense is cheap, and medication is more convenient, and side effect is rare and slight, has dissemination widely.We have also shown this point at the application in 2 years, often have nonlocal patient to make light of travelling from afar and specially come my institute to purchase medicine.What is particularly worth mentioning is that: we have found the many cases patient after interference element and other multiple Drug therapy failure, and obtain promising result with liver health bolt.
Liver health bolt also has preferably hepatoprotective, falls the enzyme effect, and this paper data shows, its hepatoprotective, enzyme falls, yellow effect is fallen and diammonium glycyrrhizinate+inosine similar.But the less rebound phenomenon that occurs after the drug withdrawal, and the liver function rebound phenomenon is very common after the diammonium glycyrrhizinate drug withdrawal.
In sum, the present invention not only provides a kind of curative effect height for Patients with Viral Hepatitis, the medicine that toxic and side effects is little, and more above-mentioned patient provides a kind of new route of administration by rectally treatment hepatitis.This suppository confirms that through the clinical practice in 5 years the effective percentage and the interferon of its treatment hepatitis B are suitable, and plurality of advantages such as administration is convenient than interferon, the healing back is difficult for bounce-back, toxic and side effects is little, and price is low are arranged.
The specific embodiment
Embodiment 1; With the semi-synthetic fatty acid glyceride is the suppository of substrate.Get semi-synthetic fatty acid glyceride 885g, be heated to 65 ℃ and make its thawing, add the Uralenic acid methyl ester 100g that had pulverized 100 mesh sieves, Lentinula edodes mycelium polysaccharide 50g, acyclovir 150g, Capric acid sodium salt 15g, stir evenly, irritate mould in the time of about 50 ℃, cooling forming, the demoulding, packing are promptly, make 1000 of suppositorys of the present invention altogether, every heavy 1.2g.
Embodiment 2: be the suppository of substrate with the semi-synthetic fatty acid glyceride.Get semi-synthetic fatty acid glyceride 900g, be heated to 70 ℃ it is melted, change over to while hot in the colloid mill of having opened, add Uralenic acid methyl ester 150g successively, Lentinula edodes mycelium polysaccharide 50g, acyclovir 90g, Capric acid sodium salt 10g, circular grinding 15 minutes, discharging, change in the suppository automatic filling machine, adjusting grain is 1.2g heavily, is filled in the compound bolt capsule of PVC/PE, and cooling, heat-sealing, shearing, packing are promptly, make 1000 of suppositorys of the present invention altogether, every heavy 1.2g.
Embodiment 3: be the suppository of substrate with the cocoa butter.Get cocoa butter 857g, be heated to 50 ℃ and make its thawing, change over to while hot in the colloid mill, open colloid mill, add Uralenic acid methyl ester 200g successively, Lentinula edodes mycelium polysaccharide 45g, acyclovir 135g, Capric acid sodium salt 13g, circular grinding 15 minutes, discharging changes in the suppository automatic filling machine, and adjusting grain heavily is 1.25g, be filled in the compound bolt capsule of PVC/PE, cooling, heat-sealing, shearing, packing promptly make 1000 of suppositorys of the present invention altogether, every heavy 1.25g.
Embodiment 4: be the suppository of substrate with the oleum sapii.Get oleum sapii 787g, be heated to about 65 ℃ and make its thawing, change over to while hot in the colloid mill, open colloid mill, add Uralenic acid methyl ester 300g successively, Lentinula edodes mycelium polysaccharide 30g, acyclovir 75g, Capric acid sodium salt 8g, circular grinding 15 minutes, make it become the slurry of uniform and delicate, change over to while hot in the suppository automatic filling machine, adjusting grain heavily is 1.2g, be filled in the compound bolt capsule of PVC/PE, cooling, heat-sealing, shearing, packing promptly make 1000 of suppositorys of the present invention altogether, every heavy 1.2g.
Embodiment 5: be the suppository of substrate with the hydrogenated vegetable oil.Get hydrogenated vegetable oil 848g, heat about 65 ℃ and make its thawing, add the Uralenic acid methyl ester 300g that has pulverized and crossed 80 mesh sieves, Lentinula edodes mycelium polysaccharide 40g, acyclovir 50g, Capric acid sodium salt 12g, stir evenly, irritate mould in the time of about 50 ℃, cooling forming, the demoulding, packing are promptly, make 1000 of suppositorys of the present invention altogether, every heavy 1.25g.
Embodiment 6: with the semi-synthetic cocos nucifera oil fat suppository that is substrate.Get semi-synthetic cocos nucifera oil fat 600g, heat about 65 ℃ it is melted, change over to while hot in the colloid mill of having opened, add Uralenic acid methyl ester 300g successively, Lentinula edodes mycelium polysaccharide 50g, acyclovir 150g, Capric acid sodium salt 15g, circular grinding 15 minutes, discharging, change over to while hot in the suppository automatic filling machine, adjusting grain is 1.115g heavily, is filled in the compound bolt capsule of PVC/PE, and cooling, heat-sealing, shearing, packing are promptly, make 1000 of suppositorys of the present invention altogether, every heavy 1.115g.
Claims (5)
1, a kind of by rectally, be used for the treatment of the suppository of viral hepatitis, comprise Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide, acyclovir and fat-soluble substrate, wherein, every bolt contains Uralenic acid methyl ester 100-300mg, Lentinula edodes mycelium polysaccharide 30-50mg, acyclovir 50-150mg.
2, described a kind of according to claim 1 by rectally, be used for the treatment of the suppository of viral hepatitis, it is characterized in that also comprising in this suppository the absorption enhancer Capric acid sodium salt, every bolt contains absorption enhancer Capric acid sodium salt 8-15mg.
3, described a kind of according to claim 1 by rectally, the suppository that is used for the treatment of viral hepatitis, it is characterized in that described fat-soluble substrate can be semi-synthetic fatty acid glyceride, among cocoa butter, oleum sapii, tristearin, fractional distillation Petiolus Trachycarpi oil, fractionated coconut oil, Brazil wax, tripalmitin, glycerol tristearate, Tridocosanoin, Ke Kemu fat, hydrogenated vegetable oil, Tween-60, Tween-65 and the SUPPOCIRE any one, every bolt contains fat-soluble substrate 600-900mg.
4, a kind of its preparation method that is used for the suppository of the described treatment viral hepatitis of claim 1 is characterized in that at first Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide, acyclovir being pulverized the 80-100 mesh sieve; Then it is joined in the fat-soluble substrate of 50-70 ℃ of thawing, grind to form the slurry of uniform and delicate while hot with colloid mill; Irritate mould, cooling forming, the demoulding, packing at last.
5, a kind of its preparation method that is used for the suppository of the described treatment viral hepatitis of claim 1, it is characterized in that at first Uralenic acid methyl ester, Lentinula edodes mycelium polysaccharide, acyclovir being joined in the fat-soluble substrate of 50-70 ℃ of thawing, grind to form the slurry of uniform and delicate while hot with colloid mill; Irritate mould, cooling forming, the demoulding, packing then.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03125305 CN1220496C (en) | 2003-08-21 | 2003-08-21 | Bougie for treating virus hepatitis and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03125305 CN1220496C (en) | 2003-08-21 | 2003-08-21 | Bougie for treating virus hepatitis and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1490016A true CN1490016A (en) | 2004-04-21 |
| CN1220496C CN1220496C (en) | 2005-09-28 |
Family
ID=34153016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03125305 Expired - Fee Related CN1220496C (en) | 2003-08-21 | 2003-08-21 | Bougie for treating virus hepatitis and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1220496C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391466C (en) * | 2006-02-17 | 2008-06-04 | 武汉大学 | Application ammonium glycyrrhizunate in preparing medicine for inflammatory enteropathy |
| US7514085B2 (en) | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
| US8758768B2 (en) | 2001-09-03 | 2014-06-24 | Glycanova As | Process for production of fungal extracellular immune stimulating compounds |
| US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
| CN115529815A (en) * | 2021-04-27 | 2022-12-27 | 广州共禾医药科技有限公司 | Pharmaceutical composition of oseltamivir or pharmaceutically acceptable salt thereof for rectal administration, preparation method and application thereof |
-
2003
- 2003-08-21 CN CN 03125305 patent/CN1220496C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8758768B2 (en) | 2001-09-03 | 2014-06-24 | Glycanova As | Process for production of fungal extracellular immune stimulating compounds |
| US9249438B2 (en) | 2001-09-03 | 2016-02-02 | Glycanova As | Production of fungal extracellular immune stimulating compounds |
| US10471135B2 (en) | 2001-09-03 | 2019-11-12 | Glycanova As | Production of fungal extracellular immune stimulating compounds |
| US7514085B2 (en) | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
| US7682615B2 (en) | 2004-07-16 | 2010-03-23 | Beka Holding As | Immune modulating compounds from fungi |
| US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
| CN100391466C (en) * | 2006-02-17 | 2008-06-04 | 武汉大学 | Application ammonium glycyrrhizunate in preparing medicine for inflammatory enteropathy |
| CN115529815A (en) * | 2021-04-27 | 2022-12-27 | 广州共禾医药科技有限公司 | Pharmaceutical composition of oseltamivir or pharmaceutically acceptable salt thereof for rectal administration, preparation method and application thereof |
| CN115529815B (en) * | 2021-04-27 | 2024-04-30 | 广州共禾医药科技有限公司 | Pharmaceutical composition of oseltamivir or pharmaceutically acceptable salt thereof for rectal administration, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1220496C (en) | 2005-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899505A (en) | Medicine composition for clearing heat and purging-fire | |
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN1220496C (en) | Bougie for treating virus hepatitis and preparing method thereof | |
| CN1923193A (en) | Application of cumarin kind compound in preparation of antiphlogistic and analgetic medicine | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN101049360A (en) | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine | |
| CN101884643B (en) | New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin | |
| CN1738633A (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| CN102824414B (en) | Medicinal tea used for treating constipation | |
| CN109224024A (en) | For preventing and treating the pharmaceutical composition and its application method of fresh-water fishes bacteria mixed infection | |
| CN1864740A (en) | A Chinese medicinal composition for clearing heat and expelling toxin and preparation method thereof | |
| CN1130212C (en) | Medicine for treating abdominal node and its preparing process | |
| CN101062097A (en) | Compound for improving and treating fatty liver disease | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1634296A (en) | Medicine for treating male infertility | |
| CN102335362A (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN1857686A (en) | Medicine composition for treating fatty liver and its preparing method | |
| CN1435244A (en) | Chinese medicine for treating hepatitis B and process for preparing same | |
| CN1301728C (en) | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1562145A (en) | Guangsheng hemp extract, its preparing method and use | |
| CN1265806C (en) | Medicinal composition for treating rheumatism | |
| CN1795901A (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN1308017C (en) | Medicine composition for treating eliminateion, dysentery and eruptive disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050928 |